
    
      This is a phase I, an open label, single dose and parallel group study to assess short term
      pharmacodynamics and safety of GSK933776. The effect on the beta amyloid levels will be
      assessed in early (MCI) and mild Alzheimer's disease (AD) patients after a single dose of
      GSK933776 by i.v. administration.
    
  